References
- Cheng RK, Kittleson MM, Beavers CJ, Birnie DH, Blankstein R, Bravo PE, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2024 May 21 [cited 2024 Nov 1];149(21). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001240
- Oe Y, Ishibashi-Ueda H, Matsuyama T, Kuo Y, Nagai T, Ikeda Y, et al. Lymph Vessel Proliferation on Cardiac Biopsy May Help in the Diagnosis of Cardiac Sarcoidosis. J Am Heart Assoc. 2019 Jan 22;8(2):e010967.
- NHS England. Clinical Commissioning Policy Statement: Positron Emission Tomography-Computed Tomography (PET-CT) Guidelines (all ages). 2017.
- Lehtonen J, Uusitalo V, Pöyhönen P, Mäyränpää MI, Kupari M. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J. 2023 May 1;44(17):1495–510.
- Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J - Cardiovasc Imaging. 2015 Jan 23;16(6):634–41.
- Wand AL, Chrispin J, Saad E, Mukherjee M, Hays AG, Gilotra NA. Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis. Front Cardiovasc Med. 2022 Jan 27;8:785279.
- Okafor J, Azzu A, Ahmed R, Ohri S, Wechalekar K, Wells AU, et al. Prognostic value of multimodality imaging in the contemporary management of cardiac sarcoidosis. Open Heart. 2024 Oct;11(2):e002989.